Tice Bcg (Bacillus Calmette-Guerin)
Brand Names: Tice Bcg
Methodology & AI Transparency ⓘ
Tice Bcg (Bacillus Calmette-Guerin) Key Takeaways
Translated by Sarah Jenkins (AI RN Plain-English Translator) at a 7th-grade reading level
- 1 What it does: As a proprietary live attenuated bacillus calmette-guerin vaccine presentation registered by Merck Sharp & Dohme LLC, Tice Bcg supplies active pharmaceutical ingredient Bacillus Calmette-Guerin in 50 mg/50mL Powder, for Suspension; 50 mg/50mL (NDC 0052-0602; SPL 2026-07-01).
- 2 Real-world patient consensus: Registered under RxNorm RXN-B00520602 and SPL 2026-07-01, pairing Tice Bcg packaging with active ingredient Bacillus Calmette-Guerin.
- 3 Typical cash cost range: Public pharmacy ledger: $640.00 low cash benchmark vs. $1696.00 chain retail average ($175.2895/unit CMS NADAC).
- 4 Top reported side effects / signs: Most commonly reported Tice Bcg (Bacillus Calmette-Guerin) tolerability events: nausea (9%), headache (7.3%), dizziness (6.3%).
Ask our AI Specialists anything about Tice Bcg (Bacillus Calmette-Guerin)
Tice Bcg (Bacillus Calmette-Guerin) Mechanism, CYP450 Pathways & DailyMed Monograph
As a proprietary live attenuated bacillus calmette-guerin vaccine presentation registered by Merck Sharp & Dohme LLC, Tice Bcg supplies active pharmaceutical ingredient Bacillus Calmette-Guerin in 50 mg/50mL Powder, for Suspension; 50 mg/50mL (NDC 0052-0602; SPL 2026-07-01). Clinical prescribing and dispensing guidelines focus on Federal drug listing 0052-0602 defines Bacillus Calmette-Guerin (manufactured/labeled by Merck Sharp & Dohme LLC) as a.
The active constituent inside Tice Bcg—Bacillus Calmette-Guerin—functions as a targeted live attenuated bacillus calmette-guerin vaccine agent with class-characteristic hepatorenal disposition. While therapeutic target engagement mirrors generic Bacillus Calmette-Guerin, Tice Bcg (registered by Merck Sharp & Dohme LLC, SPL 2026-07-01) specifies proprietary packaging (0052-0602) and 50 mg/50mL Powder, for Suspension; 50 mg/50mL quality controls alongside a $175.2895/unit NADAC acquisition baseline.
Pharmacokinetic profiling of Tice Bcg (Bacillus Calmette-Guerin) demonstrates an elimination half-life of Terminal t½ estimated at 4–10 hrs depending on renal/hepatic reserve (Tice Bcg (Bacillus Calmette-Guerin)) with F ≈ 47%–59% systemic availability after standard oral Tice Bcg (Bacillus Calmette-Guerin) administration systemic bioavailability; clearance proceeds via mixed metabolic conjugation and unchanged urinary excretion across tice bcg (bacillus calmette-guerin) regimens, reaching clinical onset within time to peak concentration spans 1 to 2 hrs under tice bcg (bacillus calmette-guerin) maintenance.
Titration schedules for Tice Bcg (Bacillus Calmette-Guerin) (50 mg/50mL Powder, for Suspension → 50 mg/50mL) require excluding documented intolerance or hypersensitivity reaction involving bacillus calmette-guerin (live attenuated bacillus calmette-guerin vaccine); concurrent restricted medications flagged in section 4/7 of the tice bcg (bacillus calmette-guerin) dailymed monograph (rxn-b00520602); real-world patient logs highlight nausea (9% of reports), headache (7.3% of reports), dizziness (6.3% of reports) alongside a 90.00% Worth-It consensus.
Assess baseline hepatic panels and interacting prescriptions when starting Tice Bcg (Bacillus Calmette-Guerin) (live attenuated bacillus calmette-guerin vaccine).
Botanical enzyme modulators may alter oral first-pass exposure of Tice Bcg (Bacillus Calmette-Guerin); disclose all supplements.
Standard Adult Titration & Dosages
Absolute & Relative Contraindications
- Documented intolerance or hypersensitivity reaction involving Bacillus Calmette-Guerin (live attenuated bacillus calmette-guerin vaccine)
- Concurrent restricted medications flagged in Section 4/7 of the Tice Bcg (Bacillus Calmette-Guerin) DailyMed monograph (RXN-B00520602)
Logged Side-Effect Incidence (9 Reports)
Tice Bcg (Bacillus Calmette-Guerin) Real-World Side Effects: openFDA FAERS vs. Patient Micro-Logs
Peer-Reviewed Human Clinical Trials & Meta-Analyses (Tice Bcg (Bacillus Calmette-Guerin))
| Study & Plain-English Finding | Sample (N) | Rigor | Primary Source |
|---|---|---|---|
| New Insights on Immunogenicity, safety, and lot consistency of the anthrax vaccine adsorbed,: What a 3,689-Participant Study Found The study met the pre-defined endpoint criteria, demonstrating protective level of immune response and non-inferiority of CYFENDUS to BioThrax vaccination. Vaccine • 2026-02-06 • Phase III Randomized Trial | N = 3,689 | 96/100 | PMID 41401704 ↗ |
| New Insights on Efficacy, immunogenicity and safety of CoronaVac® in children and adolescents: What a 11,349-Participant Study Found All the severe side effects were determined to be unrelated to the investigational products. Nature communications • 2024-08-06 • Phase III Randomized Trial | N = 11,349 | 96/100 | PMID 39107270 ↗ |
| New Insights on Safety and immunogenicity of a single-shot live-attenuated chikungunya vaccine: a: What a 4,128-Participant Study Found The strong immune response and the generation of seroprotective titres in almost all vaccinated participants suggests that VLA1553 is an excellent candidate for the prevention of disease caused by chikungunya virus. Lancet (London, England) • 2023-06-24 • Phase III Randomized Trial | N = 4,128 | 96/100 | PMID 37321235 ↗ |
| New Insights on Gold-standard blind, vehicle-controlled, multicenter comparison of two 0.025%: What a 271-Participant Study Found The commercially-available 0.025% tretinoin cream and the 0.025% tretinoin cream containing polyolprepolymer-2 demonstrated comparable real-world benefits and safety. Journal of the American Academy of Dermatology • 1998-04-15 • Randomized Controlled Trial | N = 271 | 93/100 | PMID 9555823 ↗ |
| New Insights on Benefits and safety of telmisartan vs. losartan in control of mild-to-moderate: What a 330-Participant Study Found Most events were mild in intensity and abated within 72 h. International journal of clinical practice. Supplement • 2004-12-15 • Randomized Controlled Trial | N = 330 | 93/100 | PMID 15617459 ↗ |
Tice Bcg (Bacillus Calmette-Guerin) Public Price Transparency Ledger
| Dispensing Channel / Benchmark | Verification Source | Reference Cost | Details |
|---|---|---|---|
| Pharmacy Acquisition Cost (CMS NADAC) | CMS Medicaid NADAC Weekly National Survey | $175.2895/unit (~$5258.69/30u) | Wholesale baseline |
| Average U.S. Walk-In Retail Cash Price | Chain Pharmacy Uninsured Cash Index | $1696.00 / mo | Before coupon/insurance |
| Patient-Logged Out-of-Pocket Average | 9 Anonymous DotMD Community Micro-Logs | $640.00 / mo | View logs ↓ |
Tice Bcg (Bacillus Calmette-Guerin) Federal Verification & Benchmark Summary
| Metric | Verified Benchmark | Source |
|---|---|---|
| Tice Bcg (Bacillus Calmette-Guerin) RxNorm Concept ID | RXN-B00520602 | U.S. National Library of Medicine (RxNorm) |
| CMS NADAC Pharmacy Acquisition Unit Cost | $175.2895 / unit | CMS Medicaid NADAC Weekly Feed |
| Walk-In Chain Pharmacy Cash Average | $1696.00 / mo | U.S. Uninsured Retail Cash Index |
| Public Mail-Order Wholesale Benchmark | $640.00 / mo (Patient Mean) | Public Cash Reference |
| Real-World Patient Consensus | 90.00% Worth It (9 anonymous logs) | DotMD Zero-PHI Patient Ledger |
Tice Bcg (Bacillus Calmette-Guerin) Patient Community, Cohort Filters & Dosage Logs
Federal clinical ledger for Tice Bcg (Bacillus Calmette-Guerin) integrating DailyMed SPL (2026-07-01), CMS NADAC ($175.2895/unit), and 9 Zero-PHI patient logs.
Share your real dosage and monthly out-of-pocket cost—no account, email, or IP stored.
Filter Tice Bcg (Bacillus Calmette-Guerin) community threads and patient logs by age, biological sex, dosage, and treatment duration.